LEO 27847
Alternative Names: LEO27847Latest Information Update: 02 Oct 2021
At a glance
- Originator LEO Pharma
 - Class
 - Mechanism of Action Undefined mechanism
 
- 
          
            
              Orphan Drug Status
              No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 - New Molecular Entity Yes
 
Highest Development Phases
- Discontinued Kidney disorders; Secondary hyperparathyroidism
 
Most Recent Events
- 05 Apr 2016 Discontinued - Phase-I for Kidney disorders (In volunteers) in Canada (PO, liquid)
 - 05 Apr 2016 Discontinued - Phase-I for Kidney disorders (In volunteers) in United Kingdom (PO, liquid and tablet)
 - 05 Apr 2016 Discontinued - Phase-I for Secondary hyperparathyroidism in Germany and Poland (PO)